Physician profile
Roxana Ramos
NPI 1700651197
$3,565.78
in general payments reported to CMS, 2019-2025
46 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $547 · 2024: $1,469 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.45 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $316.30 | 2023-2024 | Vegzelma |
| Genzyme Corporation | $299.04 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $241.57 | 2024-2025 | Reblozyl, Opdivo |
| Janssen Biotech, INC. | $212.14 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Novartis Pharmaceuticals Corporation | $197.12 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $194.33 | 2023-2025 | Cosela, Monoferric |
| Abbvie INC. | $185.81 | 2024-2025 | |
| Daiichi Sankyo INC. | $185.01 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $137.93 | 2024-2025 | Calquence, Enhertu, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $129.78 | 2024-2025 | Iclusig, Fruzaqla |
| Celgene Corporation | $128.25 | 2024-2025 | Reblozyl, Pomalyst, Opdualag |
| Emd Serono, INC. | $120.63 | 2023-2025 | Bavencio |
| Glaxosmithkline, LLC. | $105.61 | 2024-2025 | Ojjaara, Blenrep |
| Bayer Healthcare Pharmaceuticals INC. | $94.15 | 2024-2025 | |
| Pfizer INC. | $90.22 | 2024-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.